{"nctId":"NCT00608023","briefTitle":"TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy","startDateStruct":{"date":"2007-08"},"conditions":["Lipodystrophy","HIV Infections"],"count":263,"armGroups":[{"label":"Tesamorelin 12 months (T-T)","type":"EXPERIMENTAL","interventionNames":["Drug: Tesamorelin"]},{"label":"Tesamorelin-Placebo (T-P)","type":"EXPERIMENTAL","interventionNames":["Drug: Tesamorelin","Drug: Placebo for Tesamorelin"]},{"label":"Placebo-Tesamorelin (P-T)","type":"EXPERIMENTAL","interventionNames":["Drug: Tesamorelin","Drug: Placebo for Tesamorelin"]}],"interventions":[{"name":"Tesamorelin","otherNames":["Egrifta"]},{"name":"Placebo for Tesamorelin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who have completed the 26 weeks treatment period of the TH9507-CTR-1011 study.\n* Signed informed consent before any trial-related activities.\n\nExclusion Criteria:\n\n* Fasting blood glucose \\>8.33 mmoL (150 mg/dL) at the end of the TH9507-CTR-1011 study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Changes From Baseline in Visceral Adipose Tissue (VAT) at Week 52","description":"Visceral adipose tissue (VAT) was assessed by computerized tomography (CT) scan using a single-slice. Changes in VAT between baseline and Week 52 are reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41","spread":"57"},{"groupId":"OG001","value":"0","spread":"53"},{"groupId":"OG002","value":"-26","spread":"47"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes From Baseline in Triglycerides at Week 52","description":"Blood lipid levels were determined under fasting conditions. Changes in triglycerides between baseline and Week 52 are reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37","spread":"196"},{"groupId":"OG001","value":"4","spread":"177"},{"groupId":"OG002","value":"1","spread":"120"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes From Baseline in Total Cholesterol/HDL Cholesterol Ratio at Week 52","description":"Blood lipid levels were determined under fasting conditions. Total Cholesterol/HDL Cholesterol Ratio was obtained by dividing the total cholesterol value by the value of the HDL cholesterol. Changes between baseline and Week 52 are reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"1.75"},{"groupId":"OG001","value":"0.13","spread":"1.19"},{"groupId":"OG002","value":"0.06","spread":"1.01"}]}]}]},{"type":"PRIMARY","title":"Changes From Baseline in Fasting Blood Glucose at Week 52","description":"Blood glucose was determined after an overnight fast. Changes in blood glucose between baseline and Week 52 are reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"16"},{"groupId":"OG001","value":"-2","spread":"34"},{"groupId":"OG002","value":"1","spread":"21"}]}]}]},{"type":"PRIMARY","title":"Changes From Baseline in 2 h Oral Glucose Tolerance Test (OGTT) at Week 52","description":"Glucose tolerance was determined after an overnight fast using standard 75 gram-oral glucose tolerance test (OGTT) with glucose measured at timepoints 0, 30, 60, 90 and 120. Changes in glucose tolerance between baseline and Week 52 are reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"38"},{"groupId":"OG001","value":"2","spread":"35"},{"groupId":"OG002","value":"7","spread":"37"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":92},"commonTop":["Upper respiratory tract infection","Diarrhoea","Paresthesia","Injection site erythema","Musculosketal stiffness"]}}}